See more : Jupiter Life Line Hospitals Limited (JLHL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Theriva Biologics, Inc. (TOVX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theriva Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kalmar Oyj (KALMAR.HE) Income Statement Analysis – Financial Results
- Nutrien Ltd. (NTR) Income Statement Analysis – Financial Results
- Cloudberry Clean Energy ASA (CLOUD.OL) Income Statement Analysis – Financial Results
- Grupo Simec, S.A.B. de C.V. (SIMECB.MX) Income Statement Analysis – Financial Results
- Coelacanth Energy Inc. (CEI.V) Income Statement Analysis – Financial Results
Theriva Biologics, Inc. (TOVX)
About Theriva Biologics, Inc.
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.16M | 103.09K | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 874.10K | 506.57K | 399.38K | 400.00K | 500.00K | 500.00K | 100.00K | 100.00K | 100.00K |
| Cost of Revenue | 135.00K | 268.00K | 87.00K | 201.00K | 240.00K | 272.00K | 245.00K | 157.00K | 72.00K | 0.00 | 0.00 | 0.00 | 0.00 | 467.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 118.78K | 86.34K | 100.00K | 100.00K | 100.00K | 0.00 | 0.00 | 100.00K |
| Gross Profit | -135.00K | -268.00K | -87.00K | -201.00K | -240.00K | -272.00K | -245.00K | -157.00K | -72.00K | 0.00 | 0.00 | 0.00 | 0.00 | 2.70M | 103.09K | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 874.10K | 387.80K | 313.04K | 300.00K | 400.00K | 400.00K | 100.00K | 100.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 85.22% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 76.55% | 78.38% | 75.00% | 80.00% | 80.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 14.31M | 11.72M | 7.80M | 5.13M | 11.08M | 11.84M | 18.78M | 29.11M | 32.91M | 14.49M | 6.51M | 12.29M | 3.34M | 1.58M | 1.20M | 4.64M | 6.33M | 2.67M | 946.07K | 3.62M | 6.00M | 3.75M | 3.42M | 2.40M | 5.40M | 0.00 | 4.40M | 0.00 | 0.00 |
| General & Administrative | 7.16M | 9.86M | 6.47M | 5.03M | 4.58M | 5.73M | 7.47M | 10.14M | 8.07M | 6.01M | 5.07M | 5.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 624.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 763.00K | 5.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.78M | 9.86M | 6.47M | 5.03M | 4.58M | 5.73M | 7.47M | 10.14M | 8.07M | 6.01M | 5.83M | 5.01M | 2.59M | 2.70M | 2.58M | 2.68M | 3.81M | 1.44M | 285.70K | 4.48M | 4.55M | 2.82M | 2.28M | 3.00M | 4.60M | 7.70M | 3.00M | 6.40M | 3.60M |
| Other Expenses | -660.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.43M | 21.58M | 14.27M | 10.16M | 15.66M | 17.57M | 26.25M | 39.25M | 40.98M | 20.50M | 12.34M | 17.30M | 5.93M | 4.28M | 3.78M | 7.32M | 10.14M | 4.10M | 1.32M | 8.26M | 10.68M | 6.68M | 5.79M | 5.50M | 10.10M | 7.80M | 7.40M | 6.40M | 3.70M |
| Cost & Expenses | 21.43M | 21.58M | 14.27M | 10.16M | 15.66M | 17.57M | 26.25M | 39.25M | 40.98M | 20.50M | 12.34M | 17.30M | 5.93M | 4.75M | 3.78M | 7.32M | 10.14M | 4.10M | 1.32M | 8.26M | 10.68M | 6.80M | 5.87M | 5.60M | 10.20M | 7.90M | 7.40M | 6.40M | 3.80M |
| Interest Income | 1.44M | 512.00K | 6.00K | 44.00K | 283.00K | 67.00K | 21.00K | 37.00K | 6.00K | 3.00K | 33.00K | 33.00K | 14.00K | 413.00 | 2.97K | 128.24K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.11K | 9.88K | 13.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 135.00K | 268.00K | 87.00K | 201.00K | 240.00K | 272.00K | 245.00K | 157.00K | 72.00K | 20.00K | 43.00K | 63.00K | 201.00K | 358.71K | 382.09K | 404.62K | 199.63K | 30.68K | 2.26K | -154.13K | -130.55K | -118.78K | -86.34K | -100.00K | -100.00K | -100.00K | 0.00 | 0.00 | -100.00K |
| EBITDA | -19.85M | -21.58M | -14.19M | -9.96M | -15.42M | -17.30M | -26.01M | -39.10M | -40.91M | -20.48M | -11.53M | -17.22M | -7.48M | -1.22M | -3.34M | -6.91M | -9.94M | -4.07M | -1.28M | -8.09M | -9.76M | -6.42M | -5.39M | -5.15M | -7.90M | -7.40M | -7.30M | -6.30M | -3.60M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -38.71% | -3,158.80% | 0.00% | 0.00% | 0.00% | 0.00% | -80,946.53% | -1,116.24% | -1,266.71% | 2,407.29% | 2,025.00% | -1,940.00% | -1,480.00% | -7,300.00% | -6,400.00% | -3,500.00% |
| Operating Income | -21.43M | -21.58M | -14.27M | -10.16M | -15.66M | -17.57M | -26.25M | -39.25M | -40.98M | -20.50M | -12.34M | -17.30M | -5.93M | -1.58M | -3.68M | -7.32M | -10.14M | -4.12M | -1.36M | -8.09M | -9.68M | -6.30M | 9.70M | 8.20M | -9.60M | -7.30M | -7.30M | -6.40M | -3.40M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -50.05% | -3,571.17% | 0.00% | 0.00% | 0.00% | 0.00% | -80,946.53% | -1,107.12% | -1,243.26% | 2,428.90% | 2,050.00% | -1,920.00% | -1,460.00% | -7,300.00% | -6,400.00% | -3,400.00% |
| Total Other Income/Expenses | 1.44M | 471.00K | 6.00K | 44.00K | 283.00K | 4.15M | 10.76M | 11.45M | -3.81M | 718.00K | 21.00K | 15.00K | -1.70M | -127.21K | -43.01K | -357.00 | 245.88K | -12.50K | 1.34M | 0.00 | 79.71K | 237.55K | 172.68K | 250.00K | -1.50M | 100.00K | 7.30M | 0.00 | 200.00K |
| Income Before Tax | -19.99M | -21.11M | -14.27M | -10.12M | -15.38M | -13.42M | -15.49M | -27.80M | -44.79M | -19.78M | -12.32M | -17.28M | -7.63M | -1.71M | -3.72M | -7.32M | 0.00 | -4.13M | -1.39M | 0.00 | -9.60M | -6.06M | -5.30M | -5.00M | -9.50M | -7.20M | 0.00 | -6.30M | -3.50M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -54.07% | -3,612.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,098.00% | -1,195.96% | -1,326.94% | -1,250.00% | -1,900.00% | -1,440.00% | 0.00% | -6,300.00% | -3,500.00% |
| Income Tax Expense | -1.64M | -1.43M | -94.00K | -117.00K | -360.00K | -4.20M | -11.08M | -12.00M | 2.76M | -718.00K | -22.00K | -231.00K | 2.22M | 10.11K | 49.93K | -114.05K | -245.88K | -5.48K | 36.63K | 677.06K | -67.57K | -295.25K | 12.09M | 13.60M | 0.00 | -200.00K | 7.40M | 0.00 | 400.00K |
| Net Income | -18.35M | -19.69M | -14.17M | -10.00M | -15.02M | -13.37M | -15.17M | -27.26M | -43.74M | -19.78M | -12.32M | -17.07M | -8.15M | -1.71M | -3.73M | -7.21M | -9.89M | -4.10M | -1.36M | -8.62M | -9.48M | -5.76M | -17.38M | -18.60M | -9.50M | -7.00M | -7.40M | -6.30M | -3.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -54.07% | -3,619.60% | 0.00% | 0.00% | 0.00% | 0.00% | -86,175.82% | -1,084.45% | -1,137.68% | -4,352.97% | -4,650.00% | -1,900.00% | -1,400.00% | -7,400.00% | -6,300.00% | -3,900.00% |
| EPS | -28.49 | -32.11 | -1.16 | -5.26 | -9.14 | -21.45 | -42.70 | -101.17 | -189.68 | -111.78 | -94.40 | -171.19 | -102.93 | -26.75 | -61.26 | -122.12 | -196.76 | -442.24 | -982.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -28.48 | -32.11 | -1.16 | -5.26 | -9.14 | -21.45 | -42.70 | -101.17 | -189.68 | -111.78 | -94.40 | -171.19 | -102.93 | -26.75 | -61.26 | -122.12 | -196.76 | -442.24 | -982.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 644.00K | 613.09K | 12.19M | 1.90M | 1.64M | 623.24K | 355.33K | 269.40K | 230.58K | 176.98K | 130.48K | 99.70K | 79.17K | 63.98K | 60.91K | 59.00K | 50.28K | 9.27K | 1.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 644.28K | 613.09K | 12.19M | 1.90M | 1.64M | 623.24K | 355.33K | 269.40K | 230.58K | 176.98K | 130.48K | 99.70K | 79.17K | 63.98K | 60.91K | 59.00K | 50.28K | 9.27K | 1.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on the strength of...
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
–Phase 1 trial in collaboration with Sant Joan de Déu-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee–
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft –
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the presentation of preclinical data demonstrating...
Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript
Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
– The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), with no safety concerns raised -
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a...
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
ROCKVILLE, Md., March 11, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company's Management will provide a...
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE with no safety concerns raised; VIRAGE remains on track to complete enrollment in the first half of 2024 The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE...
Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference
ROCKVILLE, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company's Management will participate...
Source: https://incomestatements.info
Category: Stock Reports